Every Word
Carries Legal
Weight

MD, FRCPC · Certified Medical Interpreter (CMI)

The source document said "poorly differentiated." In the target language, the nearest equivalent carries a subtly different prognosis implication. I held the file for two hours until I was certain.

— Translating a Stage IV adenocarcinoma pathology report for a cross-border clinical trial — Paris to Berlin

PharmD · RAC (EU) · TOPRA Member

A single mistranslated dosage qualifier — "up to" versus "at least" — would have invalidated the entire IND dossier. The FDA reviewer flagged it. I caught it first.

— Reviewing a 900-page NDA submission for a Spanish pharmaceutical company seeking FDA approval

MD, DM (Neurology) · ATA Certified

The Japanese neurological lexicon has no direct equivalent for "pseudobulbar affect." I spent three days corresponding with the treating neurologist before committing to a rendering.

— Certifying a Phase III trial protocol for a CNS drug — Massachusetts General to Osaka University Hospital

MA Linguistics · NAATI Certified · USCIS Approved

The asylum case hinged on whether the medical examiner's notes described "scarring consistent with" or "scarring caused by" — a two-word difference between deportation and protection.

— Translating a forensic medical examination report in a credible-fear asylum proceeding — USCIS Chicago

MD (Surgery) · JMIP Certified · ISO 17100

Operative reports contain anatomical shorthand developed over decades in a single institution. Without surgical training, you cannot recognize when a term is non-standard — and that ambiguity cannot survive a Joint Commission review.

— Certifying a 47-page hepatectomy operative report for a Joint Commission international accreditation submission

PharmD · ACRP-CP · GCP Certified

Informed consent in Arabic is not translation — it is cultural transposition. A patient's right to understand what they are agreeing to depends entirely on whether the language sounds like their language, not a legal document.

— Localizing informed consent forms for a multicenter Phase II oncology trial across six MENA sites